AIM
CYTK icon

Acrospire Investment Management’s Cytokinetics CYTK Stock Holding History

Acrospire Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-81
Closed -$1K – 381
2017
Q2 		$1K Sell
81
-1,397
-95% -$19.4K ﹤0.01% 2085
2017
Q1 		$19K Sell
1,478
-1,000
-40% -$11.7K 0.02% 1651
2016
Q4 		$30K Buy
+2,478
New +$26.3K 0.01% 1630
2016
Q2 		– Sell
-7,178
Closed -$51K – 2062
2016
Q1 		$51K Buy
+7,178
New +$52.4K 0.04% 927

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Acrospire Investment Management's CYTK Position: Q3 2017 in Review

Acrospire Investment Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 81 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in CYTK in Q1 2016 and held it in 4 quarters. The position peaked at $51K in Q1 2016. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

  • Acrospire Investment Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 81 Cytokinetics shares in Q3 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Cytokinetics in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Cytokinetics position peaked at $51K in Q1 2016.
  • 132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.